Marcel E Curlin1, Timothy A Bates2, Gaelen Guzman2, Devin Schoen3, Savannah K McBride2, Samuel D Carpenter4, Fikadu G Tafesse5. 1. Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: curlin@ohsu.edu. 2. Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA. 3. Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, OR 97239, USA. 4. Department of Psychiatry, Oregon Health & Science University, Portland, OR 97239, USA. 5. Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: tafesse@ohsu.edu.
Abstract
BACKGROUND: The spread of the vaccine-resistant Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens unvaccinated and fully vaccinated individuals, and accelerated booster vaccination campaigns are underway to mitigate the ongoing wave of Omicron cases. The immunity provided by standard vaccine regimens, boosted regimens, and immune responses elicited by vaccination plus natural infection remain incompletely understood. The magnitude, quality, and durability of serological responses, and the likelihood of protection against future SARS-CoV-2 variants following these modes of exposure, are poorly characterized but are critical to the future trajectory of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: Ninety-nine individuals were semi-randomly selected from a larger vaccination cohort following vaccination and, in some cases, breakthrough infection. We analyzed spike receptor-binding domain-specific immunoglobulin G (IgG), IgA, and IgM by enzyme-linked immunosorbent assay, neutralizing antibody titers against live SARS-CoV-2 variants, and antibody-dependent cell-mediated phagocytosis. FINDINGS: In 99 vaccinated adults, compared with responses after two doses of an mRNA regimen, the immune responses 3 months after a third vaccine dose and 1 month after breakthrough infection due to prior variants show dramatic increases in magnitude, potency, and breadth, including increased antibody-dependent cellular phagocytosis and robust neutralization of the currently circulating Omicron BA.2 variant. CONCLUSIONS: Boosters and natural infection substantially boost immune responses. As the number of Omicron sub-variant cases rise and as global vaccination and booster campaigns continue, an increasing proportion of the world's population will acquire potent immune responses that may be protective against future SARS-CoV-2 variants. FUNDING: This work was funded by the M. J. Murdock Charitable Trust, the OHSU Foundation, the NIH (T32HL083808), and OHSU Innovative IDEA.
BACKGROUND: The spread of the vaccine-resistant Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens unvaccinated and fully vaccinated individuals, and accelerated booster vaccination campaigns are underway to mitigate the ongoing wave of Omicron cases. The immunity provided by standard vaccine regimens, boosted regimens, and immune responses elicited by vaccination plus natural infection remain incompletely understood. The magnitude, quality, and durability of serological responses, and the likelihood of protection against future SARS-CoV-2 variants following these modes of exposure, are poorly characterized but are critical to the future trajectory of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: Ninety-nine individuals were semi-randomly selected from a larger vaccination cohort following vaccination and, in some cases, breakthrough infection. We analyzed spike receptor-binding domain-specific immunoglobulin G (IgG), IgA, and IgM by enzyme-linked immunosorbent assay, neutralizing antibody titers against live SARS-CoV-2 variants, and antibody-dependent cell-mediated phagocytosis. FINDINGS: In 99 vaccinated adults, compared with responses after two doses of an mRNA regimen, the immune responses 3 months after a third vaccine dose and 1 month after breakthrough infection due to prior variants show dramatic increases in magnitude, potency, and breadth, including increased antibody-dependent cellular phagocytosis and robust neutralization of the currently circulating Omicron BA.2 variant. CONCLUSIONS: Boosters and natural infection substantially boost immune responses. As the number of Omicron sub-variant cases rise and as global vaccination and booster campaigns continue, an increasing proportion of the world's population will acquire potent immune responses that may be protective against future SARS-CoV-2 variants. FUNDING: This work was funded by the M. J. Murdock Charitable Trust, the OHSU Foundation, the NIH (T32HL083808), and OHSU Innovative IDEA.
Authors: Young-Jun Park; Anna De Marco; Tyler N Starr; Zhuoming Liu; Dora Pinto; Alexandra C Walls; Fabrizia Zatta; Samantha K Zepeda; John E Bowen; Kaitlin R Sprouse; Anshu Joshi; Martina Giurdanella; Barbara Guarino; Julia Noack; Rana Abdelnabi; Shi-Yan Caroline Foo; Laura E Rosen; Florian A Lempp; Fabio Benigni; Gyorgy Snell; Johan Neyts; Sean P J Whelan; Herbert W Virgin; Jesse D Bloom; Davide Corti; Matteo Samuele Pizzuto; David Veesler Journal: Science Date: 2022-01-06 Impact factor: 63.714
Authors: Laura A VanBlargan; Lucas J Adams; Zhuoming Liu; Rita E Chen; Pavlo Gilchuk; Saravanan Raju; Brittany K Smith; Haiyan Zhao; James Brett Case; Emma S Winkler; Bradley M Whitener; Lindsay Droit; Ishmael D Aziati; Traci L Bricker; Astha Joshi; Pei-Yong Shi; Adrian Creanga; Amarendra Pegu; Scott A Handley; David Wang; Adrianus C M Boon; James E Crowe; Sean P J Whelan; Daved H Fremont; Michael S Diamond Journal: Immunity Date: 2021-08-19 Impact factor: 43.474
Authors: Wanwisa Dejnirattisai; Jiandong Huo; Daming Zhou; Jiří Zahradník; Piyada Supasa; Chang Liu; Helen M E Duyvesteyn; Helen M Ginn; Alexander J Mentzer; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei Wang; Aiste Dijokaite; Suman Khan; Ori Avinoam; Mohammad Bahar; Donal Skelly; Sandra Adele; Sile Ann Johnson; Ali Amini; Thomas G Ritter; Chris Mason; Christina Dold; Daniel Pan; Sara Assadi; Adam Bellass; Nicola Omo-Dare; David Koeckerling; Amy Flaxman; Daniel Jenkin; Parvinder K Aley; Merryn Voysey; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M Siqueira; Vicky Baillie; Natali Serafin; Gaurav Kwatra; Kelly Da Silva; Shabir A Madhi; Marta C Nunes; Tariq Malik; Peter J M Openshaw; J Kenneth Baillie; Malcolm G Semple; Alain R Townsend; Kuan-Ying A Huang; Tiong Kit Tan; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Bede Constantinides; Hermione Webster; Derrick Crook; Andrew J Pollard; Teresa Lambe; Neil G Paterson; Mark A Williams; David R Hall; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; Gideon Schreiber; David I Stuart; Gavin R Screaton Journal: Cell Date: 2022-01-04 Impact factor: 41.582
Authors: Sandile Cele; Laurelle Jackson; David S Khoury; Khadija Khan; Thandeka Moyo-Gwete; Houriiyah Tegally; James Emmanuel San; Deborah Cromer; Cathrine Scheepers; Daniel G Amoako; Farina Karim; Mallory Bernstein; Gila Lustig; Derseree Archary; Muneerah Smith; Yashica Ganga; Zesuliwe Jule; Kajal Reedoy; Shi-Hsia Hwa; Jennifer Giandhari; Jonathan M Blackburn; Bernadett I Gosnell; Salim S Abdool Karim; Willem Hanekom; Anne von Gottberg; Jinal N Bhiman; Richard J Lessells; Mahomed-Yunus S Moosa; Miles P Davenport; Tulio de Oliveira; Penny L Moore; Alex Sigal Journal: Nature Date: 2021-12-23 Impact factor: 49.962
Authors: Michela Antonelli; Rose S Penfold; Jordi Merino; Carole H Sudre; Erika Molteni; Sarah Berry; Liane S Canas; Mark S Graham; Kerstin Klaser; Marc Modat; Benjamin Murray; Eric Kerfoot; Liyuan Chen; Jie Deng; Marc F Österdahl; Nathan J Cheetham; David A Drew; Long H Nguyen; Joan Capdevila Pujol; Christina Hu; Somesh Selvachandran; Lorenzo Polidori; Anna May; Jonathan Wolf; Andrew T Chan; Alexander Hammers; Emma L Duncan; Tim D Spector; Sebastien Ourselin; Claire J Steves Journal: Lancet Infect Dis Date: 2021-09-01 Impact factor: 25.071
Authors: Timothy A Bates; Savannah K McBride; Hans C Leier; Gaelen Guzman; Zoe L Lyski; Devin Schoen; Bradie Winders; Joon-Yong Lee; David Xthona Lee; William B Messer; Marcel E Curlin; Fikadu G Tafesse Journal: Sci Immunol Date: 2022-02-18
Authors: Madhumita Shrotri; Annalan M D Navaratnam; Vincent Nguyen; Thomas Byrne; Cyril Geismar; Ellen Fragaszy; Sarah Beale; Wing Lam Erica Fong; Parth Patel; Jana Kovar; Andrew C Hayward; Robert W Aldridge Journal: Lancet Date: 2021-07-17 Impact factor: 79.321